The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.

A £129 million government grant will help the firm establish new R&D centers for advancing new cancer immunotherapies including personalized mRNA vaccines.

The company plans to use the money to continue an ongoing global Phase II trial of the drug in several BRAF-altered tumor types.

Researchers tested the performance of the whole-genome sequencing-based assay head-to-head against ctDNA and ddPCR assays.

NEW YORK – Sarepta Therapeutics on Wednesday said that the UK's Medicines & Healthcare Products Regulatory Agency has lifted the clinical hold on a Phase III study of its Duchenne muscular dystrophy ...

"Dosing the first patient in the TNG456 Phase I/II trial marks a significant step for us and for patients with MTAP-deleted GBM," Adam Crystal, Tango's president of R&D, said in a statement. "People ...

Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

NEW YORK – PeproMene Bio will expand the ongoing Phase I PMB-102 study of its BAFF-R-targeted CAR T-cell therapy PMB-CT01 after showing initial efficacy in seven lymphoma patients, the firm said ...

If regulators clear the application, the firm will begin a Phase I/II trial for RJVA-001 to assess its safety, tolerability, and initial efficacy.